The estimated Net Worth of John F Milligan is at least $278 Thousand dollars as of 15 December 2020. John Milligan owns over 100,000 units of Pacific Biosciences of California Inc stock worth over $168,000 and over the last 21 years he sold PACB stock worth over $0. In addition, he makes $110,333 as Independent Chairman of the Board at Pacific Biosciences of California Inc.
Sign up
John Milligan PACB stock SEC Form 4 insiders trading
John has made over 55 trades of the Pacific Biosciences of California Inc stock since 2003, according to the Form 4 filled with the SEC. Most recently he bought 100,000 units of PACB stock worth $2,300,000 on 15 December 2020.
The largest trade he's ever made was exercising 395,635 units of Pacific Biosciences of California Inc stock on 14 November 2013 worth over $3,018,695. On average, John trades about 41,903 units every 52 days since 2003. As of 15 December 2020 he still owns at least 100,000 units of Pacific Biosciences of California Inc stock.
You can see the complete history of John Milligan stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John Milligan biography
Dr. John F. Milligan Ph.D. has been appointed as Independent Chairman of the Board of the Company effective 9/14/2020. Dr. Milligan joined Gilead Sciences Inc. in 1990 as a research scientist and was appointed Director of Project Management and Project Team Leader for the Gilead Hoffmann-La Roche Tamiflu® collaboration in 1996. In 2002, Dr. Milligan was appointed Chief Financial Officer of Gilead. He was named Gilead’s Chief Operating Officer in 2007 and President in 2008. Dr. Milligan was appointed Chief Executive Officer and elected to the board of directors of Gilead in 2016. On December 31, 2018, Dr. Milligan retired as Chief Executive Officer of Gilead and resigned from the board of directors. Dr. Milligan is the Chair of the board of trustees of Ohio Wesleyan University. Dr. Milligan received his B.A. from Ohio Wesleyan University, his Ph.D. in biochemistry from the University of Illinois and was an American Cancer Society postdoctoral fellow at the University of California at San Francisco.
What is the salary of John Milligan?
As the Independent Chairman of the Board of Pacific Biosciences of California Inc, the total compensation of John Milligan at Pacific Biosciences of California Inc is $110,333. There are 6 executives at Pacific Biosciences of California Inc getting paid more, with Michael Hunkapiller having the highest compensation of $859,188.
What's John Milligan's mailing address?
John's mailing address filed with the SEC is PACIFIC BIOSCIENCES OF CALIFORNIA, INC., 1305 O'BRIEN DRIVE, MENLO PARK, CA, 94025.
Insiders trading at Pacific Biosciences of California Inc
Over the last 14 years, insiders at Pacific Biosciences of California Inc have traded over $95,441,111 worth of Pacific Biosciences of California Inc stock and bought 2,252,330 units worth $6,097,136 . The most active insiders traders include Michael Hunkapiller, John F Milligan, and Christian O Henry. On average, Pacific Biosciences of California Inc executives and independent directors trade stock every 44 days with the average trade being worth of $202,112. The most recent stock trade was executed by Jeff Eidel on 19 August 2024, trading 26,760 units of PACB stock currently worth $42,548.
What does Pacific Biosciences of California Inc do?
pacbio develops comprehensive solutions for scientists that propel the field of genomics, improve science and research, and create positive impact globally. we provide sophisticated genomic analysis systems that deliver invaluable insights for scientists who strive to resolve complex genetic challenges. our strength comes from the dedication of our people, who are fueled by a desire to effect real, positive change. with a focus on the future and an experienced, passionate team, we are motivated to continue to redefine what is possible in genomics.
What does Pacific Biosciences of California Inc's logo look like?
Complete history of John Milligan stock trades at Gilead Sciences, Pacific Biosciences of California Inc, and 4D Molecular Therapeutics
Pacific Biosciences of California Inc executives and stock owners
Pacific Biosciences of California Inc executives and other stock owners filed with the SEC include:
-
Michael Hunkapiller,
Director -
Christian O. Henry M.B.A.,
Pres, CEO & Director -
Susan G. Kim,
Chief Financial Officer -
Dr. Denis Zaccarin Ph.D.,
Sr. VP of R&D -
William Ericson,
Independent Director -
Randall Livingston,
Independent Director -
Marshall Mohr,
Independent Director -
John Milligan,
Independent Chairman of the Board -
Lucy Shapiro,
Independent Director -
Kathy Ordonez,
Director -
Christian Henry,
President, Chief Executive Officer, Director -
David Botstein,
Independent Director -
Susan Kim,
Chief Principal Officer, Chief Accounting Officer -
Eric Schaefer,
Chief Accounting Officer, Vice President -
Denis Zaccarin,
Vice President - Semiconductor Integration Devices -
Chris Seipert,
Vice President, Sales, Service & Support, EMEA and America -
Kathleen Lynch J.D.,
Head of Global Gov. Affairs & Corp. Communications -
Michele Farmer CPA,
VP & Chief Accounting Officer -
Kathleen Lynch,
Head of Global Gov. Affairs & Corp. Communications -
Brett Atkins J.D., Ph.D.,
Gen. Counsel & Corp. Sec. -
Trevin Rard,
Head of Investor Relations -
Dr. Jonas Korlach Ph.D.,
Chief Scientific Officer -
Michele Farmer,
VP & Chief Accounting Officer -
Mark Van Oene,
Chief Operating Officer -
Dr. Stephen Turner,
Co-Founder & CTO -
James Michael Phillips,
SVP, Research & Development -
Susan K Barnes,
EVP, CFO and PAO -
Kevin P Corcoran,
SVP, Market Development -
Brook H Byers,
Director -
Jeff Eidel,
See Remarks -
Brian B Dow,
VP and PAO -
Michael Glynn,
Chief Commercial Officer -
David B Singer,
Director -
Susan E Siegel,
Director -
Hugh C Martin,
Chairman, CEO & President -
Stephen W Turner,
VP & Chief Technology Officer -
Hannah Valantine,
Director -
Oene Mark Van,
See Remarks -
Peter Fromen,
See Remarks -
Michele Farmer,
See Remarks -
David W Meline,
Director